Psychotropic Medication Usage in Pediatric CKD: Reporting from the Chronic Kidney Disease in Children Cohort

Ryan C Ward; Amy J Kogon; Matthew B Matheson; Anne Dawson; Stephen R Hooper; Stephen Molitor; Cynthia Wong; Susan L Furth; Bradley A Warady; Lyndsay A Harshman

doi:10.34067/KID.0000000000000462

Back

Psychotropic Medication Usage in Pediatric CKD: Reporting from the Chronic Kidney Disease in Children Cohort

Journal article

Open access

Peer reviewed

Psychotropic Medication Usage in Pediatric CKD: Reporting from the Chronic Kidney Disease in Children Cohort

Ryan C Ward, Amy J Kogon, Matthew B Matheson, Anne Dawson, Stephen R Hooper, Stephen Molitor, Cynthia Wong, Susan L Furth, Bradley A Warady and Lyndsay A Harshman

Kidney360, Vol.5(7), pp.967-973

07/2024

DOI: 10.34067/KID.0000000000000462

PMCID: PMC11296547

PMID: 38739451

Files and links (1)

url

https://doi.org/10.34067/KID.0000000000000462View

Published (Version of record) Open Access

Abstract

BACKGROUND Mental health disorders (MHD) within the pediatric chronic kidney disease (CKD) population are prevalent. The frequency is unknown with which psychotropic medications that commonly treat these conditions are used in this population. METHODS Data from the Chronic Kidney Disease in Children (CKiD) cohort study were utilized to describe the use of psychotropic medications and patient-related characteristics of use. Medications were classified into 3 groups: antidepressants, CNS stimulants, and antipsychotic/mood stabilizing medications. Participant age, sex, CKD severity, and duration of medication use were ascertained. Medication use was evaluated in parallel with CKD disease type, presence of urological comorbidity, and hypertension. Chi-square tests compared subgroup medication use. RESULTS Among 1074 CKiD participants (median baseline age 9.8 years), 6% (n=60) of participants used psychotropic medications at study entry with 11% reporting incident use of any medication category (n=120). CNS stimulants were most common at baseline. Antidepressants were more frequent among incident users at 7%. Use of two or more medications was rare (3%). Median eGFR at medication initiation was 45 ml/min|1.73m2. CNS stimulants were reported at a higher rate in males compared to females (p<0.05). CONCLUSIONS 11% of CKiD patients report incident use of any psychotropic medication, with 7% reporting incident use of antidepressants. Future work is warranted to better ascertain the frequency, safety, and efficacy of psychotropic medication usage in relationship to formal MHD diagnoses in the pediatric CKD population.

Details

Title: Subtitle: Psychotropic Medication Usage in Pediatric CKD: Reporting from the Chronic Kidney Disease in Children Cohort
Creators: Ryan C Ward - University of Iowa
Amy J Kogon - Children's Hospital of Philadelphia
Matthew B Matheson - Johns Hopkins University
Anne Dawson - Nationwide Children's Hospital
Stephen R Hooper - University of North Carolina at Chapel Hill
Stephen Molitor - Medical College of Wisconsin
Cynthia Wong - Lucile Packard Children's Hospital
Susan L Furth - University of Pennsylvania
Bradley A Warady - Children's Mercy Hospital
Lyndsay A Harshman - University of Iowa
Resource Type: Journal article
Publication Details: Kidney360, Vol.5(7), pp.967-973
DOI: 10.34067/KID.0000000000000462
PMID: 38739451
PMCID: PMC11296547
NLM abbreviation: Kidney360
eISSN: 2641-7650
Language: English
Electronic publication date: 05/13/2024
Date published: 07/2024
Academic Unit: Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Radiation Oncology
Record Identifier: 9984627151402771

Metrics

11 Record Views